Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM)

CompletedOBSERVATIONAL
Enrollment

7,247

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

January 25, 2021

Study Completion Date

December 31, 2021

Conditions
FeverInfectionInflammation
Interventions
DIAGNOSTIC_TEST

Validation of biomarker

Trial Locations (1)

W2 1PG

Imperial College London, London

Sponsors
All Listed Sponsors
collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

University of Liverpool

OTHER

collaborator

University of Newcastle Upon-Tyne

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

National and Kapodistrian University of Athens

OTHER

collaborator

Stichting Katholieke Universiteit

OTHER

collaborator

University of Graz

OTHER

collaborator

University of Ljubljana

OTHER

collaborator

Riga Stradins University

OTHER

collaborator

Medical Research Council Unit, The Gambia

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

University of Bern

OTHER

collaborator

University of Oxford

OTHER

collaborator

University Hospital, Paris

OTHER

collaborator

University of Santiago de Compostela

OTHER

collaborator

Servicio Gallego de Salud

OTHER_GOV

collaborator

BioMérieux

INDUSTRY

collaborator

Micropathology Ltd, University of Warwick

INDUSTRY

lead

Imperial College London

OTHER

NCT03502993 - Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM) | Biotech Hunter | Biotech Hunter